keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy induced nausea and vomiting

keyword
https://www.readbyqxmd.com/read/29764184/efficacy-of-the-combination-neurokinin-1-receptor-antagonist-palonosetron-and-dexamethasone-compared-to-others-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#1
Ronald Chow, May Tsao, Leonard Chiu, Marko Popovic, Milica Milakovic, Henry Lam, Carlo DeAngelis
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV), a common side effect of chemotherapy, can substantially impair a patient's quality of life, interfere with a patient's compliance with anticancer therapy, and result in the manifestation of adverse events such as electrolyte imbalance, dehydration and malnutrition. The most recent guidelines published by the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO) recommend the combination of dexamethasone (DEX), a 5-hydroxytrypatmine-3 receptor antagonist (5-HT3RA), preferably palonosetron (PALO), and a neurokinin-1 receptor antagonist (NK1RA) for prophylactic treatment of CINV in patients receiving highly emetogenic chemotherapy (HEC)...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29764183/a-pilot-study-with-palonosetron-in-the-prophylaxis-of-radiation-induced-nausea-and-vomiting
#2
Vithusha Ganesh, Leah Drost, Carlo DeAngelis, Bo Angela Wan, Mark Pasetka, Stephanie Chan, Liying Zhang, May Tsao, Elizabeth Barnes, Natalie Pulenzas, Hans Chung, Pearl Zaki, Caitlin Yee, Edward Chow
BACKGROUND: Palonosetron is an effective antiemetic in chemotherapy-induced nausea and vomiting (CINV), but has yet to be studied in the radiation setting. The purpose of the present study was to investigate the efficacy and safety of palonosetron in the prophylaxis of radiation-induced nausea and vomiting (RINV). METHODS: Patients without existing nausea and vomiting undergoing palliative radiotherapy to sites with emetic risk were prescribed palonosetron 0.5 mg orally before the start of radiation treatment, and every other day until completion of treatment...
April 2018: Annals of Palliative Medicine
https://www.readbyqxmd.com/read/29744791/olanzapine-as-antiemetic-drug-in-oncology-a-retrospective-study-in-non-responders-to-standard-antiemetic-therapy
#3
Florian Slimano, Florence Netzer, Isabelle Borget, François Lemare, Benjamin Besse
Background The role of olanzapine in the treatment of chemotherapy-induced nausea and vomiting (CINV) in addition to the antiemetic therapeutic combination with aprepitant, setrons, and corticosteroids has not been well defined. Objective To investigate the effectiveness of the addition of olanzapine to a standard triplet therapy for the prevention of CINV in patients who experienced CINV during their first chemotherapy course, despite receiving a well-managed prevention protocol. Setting One comprehensive cancer centre in France...
May 9, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/29724299/comparison-of-antiemetic-effects-of-granisetron-and-palonosetron-in-patients-receiving-bendamustine-based-chemotherapy
#4
M Uchida, T Nakamura, Y Makihara, K Suetsugu, H Ikesue, Y Mori, K Kato, M Shiratsuchi, K Hosohata, T Miyamoto, K Akashi
The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed...
May 1, 2018: Die Pharmazie
https://www.readbyqxmd.com/read/29722791/phase-3-safety-study-of-intravenous-nepa-a-novel-fixed-antiemetic-combination-of-fosnetupitant-and-palonosetron-in-patients-receiving-highly-emetogenic-chemotherapy
#5
L Schwartzberg, E Roeland, Z Andric, D Kowalski, J Radic, D Voisin, G Rizzi, R Navari, R J Gralla, Meinolf Karthaus
Background: NEPA, an oral fixed combination of the NK1RA netupitant (300mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50mg), is the first fixed antiemetic combination to have been approved. A single oral NEPA capsule plus dexamethasone (DEX) given prior to AC and non-AC highly emetogenic chemotherapy (HEC) showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) over PALO plus DEX for 5 days post-chemotherapy. The safety of NEPA was well-established in the Phase 2/3 clinical program in 1169 NEPA-treated patients...
May 2, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29702540/safety-of-dexamethasone-for-nausea-and-vomiting-prophylaxis-in-children-receiving-hematopoietic-stem-cell-transplantation
#6
Edric Paw Cho Sing, Tal Schechter, Muhammad Ali, Lillian Sung, L Lee Dupuis
BACKGROUND: Many children undergoing hematopoietic stem cell transplantation (HSCT) experience chemotherapy-induced nausea and vomiting (CINV) despite receiving prophylaxis. Guideline-consistent CINV prophylaxis includes dexamethasone, but uncertainty with regard to safety potentially limits the use of dexamethasone in children. We describe immediate adverse events (AEs) attributable to dexamethasone given for CINV prophylaxis to children during HSCT conditioning. MATERIALS AND METHODS: Children enrolled in a previous prospective study were retrospectively analyzed...
April 26, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29697417/chinese-herbal-medicines-in-the-prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting
#7
Chang Lv, Chengjin Shi, Lifen Li, Xuesen Wen, Cory J Xian
PURPOSE OF REVIEW: Chemotherapy-induced nausea and vomiting (CINV) critically impact on cancer patients' quality of life, causing various complications, and increasing the risk of chemotherapeutic failure. Current treatments addressing CINV are reasonably costly and have many side effects. Chinese herbal medicines (CHMs) have been widely used in treating CINV in China. Clinical trials and modern experimental studies on CINV using CHMs are reviewed for clues that may help us to better prevent and treat CINV with CHMs, and develop safe and effective treatments...
April 24, 2018: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/29693712/effects-of-rolapitant-administered-intravenously-on-the-pharmacokinetics-of-a-modified-cooperstown-cocktail-midazolam-omeprazole-warfarin-caffeine-and-dextromethorphan-in-healthy-subjects
#8
Xiaodong Wang, Zhi-Yi Zhang, Sujata Arora, Jing Wang, Sharon Lu, Dan Powers, Vikram Kansra
Rolapitant is a selective, long-acting neurokinin-1 receptor antagonist, approved in the United States and Europe for prevention of delayed chemotherapy-induced nausea and vomiting in adults. This open-label study evaluated the effects of a new intravenous formulation of rolapitant on cytochrome P450 (CYP) enzyme (CYP3A, CYP1A2, CYP2C9, CYP2C19, and CYP2D6) activity. On days 1 and 14, 36 healthy volunteers received a modified Cooperstown cocktail (midazolam 3 mg [CYP3A substrate], caffeine 200 mg [CYP1A2 substrate], S-warfarin 10 mg [CYP2C9 substrate] + vitamin K 10 mg, omeprazole 40 mg [CYP2C19 substrate], and dextromethorphan 30 mg [CYP2D6 substrate])...
April 25, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29690798/acute-chemotherapy-induced-nausea-and-vomiting-in-children-with-cancer-still-waiting-for-a-common-consensus-on-treatment
#9
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Paola Coccia, Silvia Triarico, Giorgio Attiná
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common treatment side-effects, and remains a significant concern, in children undergoing chemotherapy. Although adult patients receive chemotherapy regimens combined with appropriate standardized antiemetic treatment, children can receive markedly varying antiemetic treatments. A narrative review of CINV was performed regarding CINV definition, scoring system, prevention and treatment, specifically focussing on studies conducted with paediatric oncology patients...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29682620/a-prospective-cohort-study-of-patient-reported-vomiting-retching-nausea-and-antiemetic-use-during-neoadjuvant-long-course-radiation-therapy-and-concurrent-5-fluorouracil-based-chemotherapy-for-rectal-adenocarcinoma
#10
Kristopher Dennis, Liang Zeng, Carlo De Angelis, Hans Chung, Natalie Coburn, Edward Chow, C Shun Wong
Background and purpose: Antiemetic guidelines suggest daily prophylaxis with a serotonin3 receptor antagonist (5-HT3 RA) as an option for patients receiving long-course neoadjuvant radiation therapy and concurrent 5-fluorouracil-based chemotherapy for rectal cancer, despite the risks that 5-HT3 RA-induced constipation may pose. We explored the incidence of patient-reported vomiting, retching, nausea and antiemetic intake among patients in this setting to determine if these risks are justified...
March 2018: Clinical and Translational Radiation Oncology
https://www.readbyqxmd.com/read/29679139/reality-of-the-emetogenic-level-of-irinotecan
#11
Maria-Angeles Garcia-Del-Barrio, Salvador Martin-Algarra, Azucena Aldaz Pastor
PURPOSE: To assess the emetogenic potential of different chemotherapy (CT) regimens in daily clinical practice in an outpatient setting. To optimize antiemetic prophylaxis if necessary METHODS: Prospective and retrospective review of the emetogenic potential of CT regimens used in adult patients in an outpatient setting RESULTS: We assess the chemotherapy-induced nausea and vomiting (CINV) of 50 different CT regimens used on 157 different patients in an outpatient setting. We found that the CT usually classified as highly emetogenic, including cisplatin and anthracycline-cyclophosphamide combination, had the higher incidence of CINV (37...
April 21, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29674800/olanzapine-versus-aprepitant-for-the-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients-receiving-doxorubicin-cyclophosphamide-regimen-a-prospective-nonrandomized-open-label-study
#12
G Shivaprakash, Karthik S Udupa, V Sarayu, Joseph Thomas, Vishal Gupta, L C Pallavi, Sudhakar Pemminati
OBJECTIVE: Despite the guideline-directed therapy, complete absence of nausea was noted only in 33% of breast cancer patients on anthracycline-cyclophosphamide regimen. Hence, we sought to compare the efficacy of aprepitant (APT) versus olanzapine (OLP) in preventing chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients on doxorubicin-cyclophosphamide regimen. PATIENTS AND METHODS: A prospective, open-label, nonrandomized study was conducted at the Department of Oncology...
November 2017: Indian Journal of Pharmacology
https://www.readbyqxmd.com/read/29667586/drug-drug-interactions-with-aprepitant-in-antiemetic-prophylaxis-for-chemotherapy
#13
R Schoffelen, A G Lankheet, C M L van Herpen, J J M van der Hoeven, I M E Desar, C Kramers
In the current guidelines to prevent hemotherapyinduced nausea and vomiting, multiple antiemetic drugs are administered simultaneously. In patients who receive highly emetogenic chemotherapy, aprepitant, an NK1-receptor antagonist, is combined with ondansetron and dexamethasone. Aprepitant can influence the pharmacokinetics of other drugs, as it is an inhibitor and inducer of CYP3A4. Some anticancer drugs and other co-medication frequently used in cancer patients are CYP3A4 or CYP29C substrates. We give an overview of the metabolism and current data on clinically relevant drug-drug interactions with aprepitant during chemotherapy...
April 2018: Netherlands Journal of Medicine
https://www.readbyqxmd.com/read/29655943/effects-of-a-histamine-h-4-receptor-antagonist-on-cisplatin-induced-anorexia-in-mice
#14
Kouichi Yamamoto, Rikuya Okui, Atsushi Yamatodani
Cancer chemotherapy often induces gastrointestinal symptoms such as anorexia, nausea, and vomiting. Antiemetic agents are effective in inhibiting nausea and vomiting, but patients still experience anorexia. We previously reported that chemotherapeutic agent-induced anorexia is associated with an increase of inflammatory cytokines. Other studies also reported that antagonism of the histamine H4 receptor is anti-inflammatory. In this study, we investigated the involvement of the H4 receptor in the development of chemotherapy-induced anorexia in mice...
April 12, 2018: Neuroscience Letters
https://www.readbyqxmd.com/read/29651918/updated-report-on-incidence-of-infusion-site-reactions-associated-with-peripheral-intravenous-administration-of-fosaprepitant
#15
Eric Chau, Jordan Lundberg, Gary Phillips, Michael Berger, Robert Wesolowski
Purpose Fosaprepitant (Emend®) is an antiemetic frequently used for the prevention of chemotherapy-induced nausea and vomiting. We previously documented an overall 28.7% incidence of infusion-site reactions in patients receiving fosaprepitant via peripheral venous access. These data resulted in a practice change within our institution; fosaprepitant is administered in more dilute concentrations over 30 min to prevent these adverse events. This retrospective study explored the impact of this practice change on the incidence of infusion-site reactions...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29606854/rucaparib-a-novel-parp-inhibitor-for-brca-advanced-ovarian-cancer
#16
REVIEW
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza
Rucaparib is a potent small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP) proteins (PARP-1, PARP-2 and PARP-3) that play an important role in repairing DNA damage and maintaining genomic stability. Tumors with mutations in BRCA1/2 or other homologous recombination deficiency (HRD) genes are particularly sensitive to PARP inhibitors because of "synthetic lethality", whereby a therapeutic agent can take advantage of an intrinsic weakness in DNA repair. Rucaparib has been investigated in several preclinical and clinical studies showing promising activity in BRCA -mutant and BRCA -wild-type epithelial ovarian cancers (EOCs)...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29589051/-chemotherapy-induced-nausea-and-vomiting-current-recommendations-for-prophylaxis
#17
REVIEW
E Storz, J E Gschwend, M Retz
The chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent side effects in cytostatic therapy and a profound challenge during the therapy of cancer patients. Therefore, standardized guideline-orientated prophylaxis is essential and a fundamental contribution for the success of treatment. This review summarizes the current recommendations for CINV of the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the S3-guideline Supportive Therapie of the Leitlinienprogramm Onkologie and shall facilitate its use in the daily routine...
March 27, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29587608/a-pilot-study-to-assess-the-pharmacy-impact-of-implementing-a-chemotherapy-induced-nausea-or-vomiting-collaborative-disease-therapy-management-in-the-outpatient-oncology-clinics
#18
Kasey Jackson, Cathy Letton, Andy Maldonado, Andrew Bodiford, Amy Sion, Rebekah Hartwell, Anastasia Graham, Carolyn Bondarenka, Lynn Uber
Background Collaborative drug therapy management is a formal partnership between a pharmacist and physician to allow the pharmacist to manage a patient's drug therapy. Literature supports collaborative disease therapy management can improve patient outcomes, improve medication adherence, enhance medication safety, and positively influence healthcare expenditures. Chemotherapy induced nausea or vomiting is considered one of the most distressing and feared adverse events among patients receiving chemotherapy...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29577093/evaluation-of-a-neurokinin-1-antagonist-in-preventing-multiple-day-cisplatin-induced-nausea-and-vomiting
#19
Quanfu Li, Wenjuan Wang, Gang Chen, Shuqin Deng, Caihong Jiang, Feng Chen, Jun Zhao, Hui Li, Xiaojun Bai, Yuliang Hu, Lenggaowa Da, Yungaowa Wu, Gaowa Jin
Objective: To perform a prospective non-randomized comparison of the effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment with the standard multiple-day cisplatin regimen for the prevention of cisplatin-induced nausea and vomiting (CINV). Methods: Patients being administered 3-day cisplatin-based chemotherapy (25 mg/m2 /d) who had never received aprepitant were given either the standard regimen (tropisetron and dexamethasone) or the aprepitant regimen (aprepitant plus tropisetron and dexamethasone)...
2018: Open Medicine (Warsaw, Poland)
https://www.readbyqxmd.com/read/29556813/bringing-it-all-together-in-the-treatment-of-cinv-application-of-current-knowledge-into-routine-clinical-practice
#20
David Warr
For patients with cancer, the threat of chemotherapy-induced nausea and vomiting (CINV) can greatly influence treatment decisions and overall quality of life. Clinicians now have numerous effective antiemetic therapies to offer to patients, but selecting the optimal strategy can be complicated. Integration of current CINV guidelines, emerging data from recent clinical trials, and patient-specific risk factors can greatly improve antiemetic prophylaxis. Two challenging clinical scenarios are presented and discussed to provide insight on how to best approach these types of treatment decisions and apply recent advances in CINV prevention and management to patient care...
March 19, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
28476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"